



PRESS RELEASE

28 July 2025 08:30:00 CEST

AcouSort's AcouWash technology enables centrifuge-free cell radiolabeling using acoustophoresis

AcouSort AB (ticker: ACOU) today announced that the prestigious US National Institute of Health / National Cancer Institute (NIH/NCI) has published a new paper on developing processes for radiolabeling using AcouSort's AcouWash technology. The article was published in Scientific Reports, a journal from the Nature portfolio.

"We are very pleased that the NIH, which is an important reference customer, has produced additional positive results in their new study. This also verifies our strategy of using benchtop systems as platforms for developing applications of our technology," said AcouSort's CEO Torsten Freltoft.

The article, titled *Centrifuge-free cell radiolabeling using acoustophoresis*, was authored by Dr. Stephen S Adler. Co-authors are Emma Stevenson, Julia Alsved, Peter L. Choyke and Noriko Sato.

Tracking ex vivo radiolabeled cells using radionuclide imaging such as positron emission tomography is an emerging method for evaluating efficacy of cell-based therapies. Traditional radiolabeling requires multiple centrifugation steps for labeling and removal of unbound radiotracers. With the goal of automating the radiolabeling procedure, Dr. Adler and his team used AcouSort's AcouWash system for the procedure, eliminating the need of using a centrifuge.

The results published in Scientific Reports demonstrate that the radiolabeling can be performed entirely using acoustophoresis, which paves the way for developing a fully automated radiolabeling device based on acoustophoresis technology.

NIH was AcouSort's first AcouWash customer and purchased the first prototype system in 2017 followed by an AcouWash 2 system in 2023. It has since used the system for demonstrating all important cell wash and up concentration steps in their development of a new method for cancer treatment monitoring.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com



PRESS RELEASE

28 July 2025 08:30:00 CEST

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is DNB Carnegie Investment Bank AB.